Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2026-02-03 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase financial products. It includes specifics about authorized cash management, amounts, investment products, expected yields, risk controls, and compliance with disclosure rules. The content focuses on updates about financing activities related to the company's own funds and investments in financial products, rather than financial results, management changes, or legal matters. It is not a full financial report, earnings release, or management discussion. The document is a regulatory announcement about capital management and financing activities, fitting the Capital/Financing Update (CAP) category.
2026-02-03 Chinese
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, methods, timing, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report content. The document is a regulatory announcement about a planned shareholding reduction, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial statement.
2026-01-19 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's use of idle funds to purchase financial products, including specifics about authorized cash management, amounts, counterparties, risk controls, and compliance with stock exchange disclosure rules. It includes tables of financial product details, dates, and risk disclosures. There is no indication that this is a full financial report, audit report, earnings release, or management discussion. It is not a regulatory certification or a brief announcement of a report publication. The content focuses on capital management and financing activities related to the company's own funds and investments. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8430 characters) supports it being a substantive update rather than a brief notice.
2026-01-06 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and related disclosures. The document references specific meetings and approvals related to the use of idle raised funds and provides detailed tables of entrusted financial products. It is a regulatory disclosure about the company's cash management activities involving raised funds, not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the transactions and risk controls. The document fits best into the category of Capital/Financing Update (CAP) as it updates on the company's use of capital raised and its investment in financial products.
2026-01-06 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about authorized cash management, investment in structured deposits, risk control measures, and detailed tables of entrusted financial products. The document is an update on capital management activities related to fundraising proceeds, focusing on the use of idle raised funds for financial management. It does not contain financial statements, earnings data, or audit information. It is not a report publication announcement since it contains substantive details and is not merely stating that a report is attached or published elsewhere. The content aligns with updates on company fundraising and capital usage activities, which fits the category of Capital/Financing Update (CAP).
2025-12-03 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the fourth board of directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. It is an official announcement related to board decisions, specifically about the use of idle funds for cash management. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-12-03 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.